Title: Ozempic Shows Anti-Aging Effects in First Clinical Trial, Reversing Biological Age by 3.1 Years

URL Source: https://trial.medpath.com/news/5c43f09ebb6d0f8e/ozempic-shows-anti-aging-effects-in-first-clinical-trial-reversing-biological-age-by-3-1-years

Published Time: 2025-08-01T17:22:31+0000

Markdown Content:
Ozempic Shows Anti-Aging Effects in First Clinical Trial, Reversing Biological Age by 3.1 Years

===============

[![Image 1: MedPath](https://trial.medpath.com/medpath-brand.png)](https://trial.medpath.com/)

[![Image 2: MedPath](https://trial.medpath.com/medpath-brand.png)](https://trial.medpath.com/)

Products

[Clinical Trials Find trials by condition, location & phase](https://trial.medpath.com/clinical-trial)[Drug Monographs Browse drug monographs and information](https://trial.medpath.com/drug)[Companies Explore organizations and their profiles](https://trial.medpath.com/organization)[News Latest updates on trials and healthcare](https://trial.medpath.com/news)

[Marketed Drugs Approved products by global authorities](https://trial.medpath.com/drug/approvals)

[FDA (US)](https://trial.medpath.com/drug/approvals/fda)[EMA (EU)](https://trial.medpath.com/drug/approvals/ema)[HSA (SG)](https://trial.medpath.com/drug/approvals/hsa)[NMPA (CN)](https://trial.medpath.com/drug/approvals/nmpa)[PPB (HK)](https://trial.medpath.com/drug/approvals/ppb)[TGA (AU)](https://trial.medpath.com/drug/approvals/tga)[HC (CA)](https://trial.medpath.com/drug/approvals/canada)[CIMA AEMPS (ES)](https://trial.medpath.com/drug/approvals/cima-aemps)[Philippines FDA (PH)](https://trial.medpath.com/drug/approvals/philippines)[Saudi SFDA (SA)](https://trial.medpath.com/drug/approvals/sfda)[NPRA (MY)](https://trial.medpath.com/drug/approvals/npra)[UK EMC (UK)](https://trial.medpath.com/drug/approvals/emc)

[### AI-Powered Research Discover powerful insights with advanced AI analysis tools for clinical trials. Learn more →](https://trial.medpath.com/research)[### Premium Access Get unlimited access to our comprehensive pharmaceutical database and analytics. Subscribe →](https://trial.medpath.com/pricing)

[Research](https://trial.medpath.com/research)

[Pricing](https://trial.medpath.com/pricing)

[FAQ](https://trial.medpath.com/faq)

Ozempic Shows Anti-Aging Effects in First Clinical Trial, Reversing Biological Age by 3.1 Years
===============================================================================================

6 days ago 3 min read

Feedback

Share

[](https://twitter.com/intent/tweet?text=Ozempic%20Shows%20Anti-Aging%20Effects%20in%20First%20Clinical%20Trial%2C%20Reversing%20Biological%20Age%20by%203.1%20Years&url=https%3A%2F%2Ftrial.medpath.com%2Fnews%2F5c43f09ebb6d0f8e%2Fozempic-shows-anti-aging-effects-in-first-clinical-trial-reversing-biological-age-by-3-1-years "Share on Twitter")[](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Ftrial.medpath.com%2Fnews%2F5c43f09ebb6d0f8e%2Fozempic-shows-anti-aging-effects-in-first-clinical-trial-reversing-biological-age-by-3-1-years "Share on LinkedIn")[](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Ftrial.medpath.com%2Fnews%2F5c43f09ebb6d0f8e%2Fozempic-shows-anti-aging-effects-in-first-clinical-trial-reversing-biological-age-by-3-1-years "Share on Facebook")

### Key Insights

*     
A randomized controlled trial of 108 people with HIV-associated lipohypertrophy found that weekly Ozempic treatment for 32 weeks reversed biological age by an average of 3.1 years.

*     
The study used epigenetic clocks to measure biological aging, showing the most pronounced anti-aging effects in the inflammatory system and brain, where aging was delayed by almost 5 years.

*     
Researchers believe the anti-aging effects stem from semaglutide's ability to improve fat distribution and reduce inflammation, both major drivers of cellular aging.

The diabetes drug Ozempic has demonstrated remarkable anti-aging effects in the first clinical trial to directly measure its impact on biological aging, with participants becoming an average of 3.1 years biologically younger after 32 weeks of treatment. The findings provide the strongest evidence yet that GLP-1 drugs like semaglutide may offer benefits far beyond their established roles in diabetes management and weight loss.

First Direct Clinical Evidence of Anti-Aging Effects
----------------------------------------------------

Varun Dwaraka from diagnostics company TruDiagnostic in Lexington, Kentucky, led a randomized controlled trial involving 108 people with HIV-associated lipohypertrophy, a condition characterized by excess fat accumulation and accelerated cellular aging. Half the participants received weekly Ozempic injections for 32 weeks, while the other half received a placebo.

The researchers used epigenetic clocks to assess biological aging - sophisticated tools that identify patterns of DNA methylation, chemical tags that affect gene activity and shift predictably with age. These patterns can be accelerated or slowed by lifestyle factors, meaning biological age can differ significantly from chronological age.

"Those on semaglutide became, on average, 3.1 years biologically younger by the end of the study," Dwaraka reported. The placebo group showed no significant change in biological age over the same period.

Organ-Specific Anti-Aging Benefits
----------------------------------

The anti-aging effects weren't uniform across all body systems. The research team found that semaglutide slowed biological aging in several organs and systems, with the most dramatic improvements occurring in the inflammatory system and brain, where the drug appeared to delay biological aging by almost 5 years. Significant benefits were also observed in the heart and kidneys.

"Semaglutide may not only slow the rate of ageing, but in some individuals partially reverse it," Dwaraka noted, highlighting the potential for the drug to actually turn back the biological clock rather than simply slowing its progression.

Mechanisms Behind the Anti-Aging Effects
----------------------------------------

The researchers believe semaglutide's anti-aging properties stem from its effects on fat distribution and metabolic health. Excess fat around organs triggers the release of pro-aging molecules that alter DNA methylation in key aging-related genes. By reducing this harmful fat accumulation and preventing low-grade inflammation - both major drivers of epigenetic aging - semaglutide appears to create a more youthful biological environment.

Randy Seeley from the University of Michigan Medical School expressed little surprise at the findings, explaining that the drugs "reduce the metabolic burden on a wide range of cells and lower inflammation. Both are major drivers of ageing in many different types of cells." However, he believes much of the benefit stems not from semaglutide's direct cellular effects, but from broader improvements to overall health.

Broader Implications and Future Directions
------------------------------------------

While the study focused specifically on people with HIV-associated lipohypertrophy, the biological pathways affected by semaglutide aren't unique to this condition. "Therefore, it is plausible that similar effects on epigenetic ageing could be observed in other populations," Dwaraka explained, suggesting the anti-aging benefits could extend to the general population.

Despite the promising results, Dwaraka cautioned against rushing to prescribe semaglutide broadly as an anti-aging therapy. "Prescribing it more broadly as an anti-ageing therapy is premature," he stated. However, he noted that the study adds momentum to ongoing efforts to repurpose existing drugs for age-related problems, which could speed approval processes and reduce the risk of unexpected side effects.

The research represents a significant milestone in understanding the full therapeutic potential of GLP-1 drugs, which have already gained prominence for treating type 2 diabetes and obesity, and are being explored for cardiovascular disease, addiction, and dementia. "Semaglutide may well emerge as one of the most promising candidates in this space," Dwaraka concluded.

![Image 3: Subscribe Icon](https://trial.medpath.com/icon_subscribe_email.webp)

### Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Subscribe Now

Related News
------------

Apr 23,

2025

### [Semaglutide Shows Promise for Slowing Biological Aging and Improving Cognition in HIV Patients](https://trial.medpath.com/news/514c83cbb482dde7/semaglutide-shows-promise-for-slowing-biological-aging-and-improving-cognition-in-hiv-patients)

Feb 3,

2025

### [Omega-3 Supplementation Shows Promise in Slowing Biological Aging, Clinical Trial Reveals](https://trial.medpath.com/news/e311993166c88e3c/omega-3-supplementation-shows-promise-in-slowing-biological-aging-clinical-trial-reveals)

Nov 28,

2024

### [Metformin Shows Promise in Slowing Cellular Aging in Primates, Suggesting Potential for Human Application](https://trial.medpath.com/news/366cf4877f83b604/fda-approved-diabetes-drug-significantly-slows-down-aging-the-brighter-side-of-news)

Oct 27,

2024

### [Semaglutide Shows Promise in Reducing Alzheimer's Risk in Type 2 Diabetes Patients](https://trial.medpath.com/news/364f0fa8163680a9/ozempic-shows-promise-against-alzheimer-s-disease-the-pinnacle-gazette)

Oct 24,

2024

### [Semaglutide Associated with Reduced Alzheimer's Risk in Type 2 Diabetes Patients](https://trial.medpath.com/news/567ec346ee7a6de3/ozempic-linked-to-lower-alzheimer-s-risk-in-people-with-type-2-diabetes-nbc-news)

Sep 16,

2024

### [GLP-1 Agonists Like Ozempic Show Promise in Halting Progression of Diabetes-Linked Liver Disease](https://trial.medpath.com/news/57805efd8f99772c/ozempic-could-curb-progression-of-diabetes-linked-liver-disease)

Oct 3,

2023

### [Semaglutide Shows Sustained Benefits in Blood Sugar Control and Weight Loss Over Three Years](https://trial.medpath.com/news/8f7a2b8661530dcf/ozempic-wegovy-improve-blood-sugar-control-and-weight-loss-over-3-years-study-finds)

Sep 10,

2019

### [Small Clinical Trial Shows Drug Cocktail Reverses Biological Age by 2.5 Years](https://trial.medpath.com/news/2a0115507edfaca7/small-clinical-trial-shows-drug-cocktail-reverses-biological-age-by-2-5-years)

Sources
-------

### [Ozempic Shows Anti-Aging Effects in First Clinical Trial, Reversing ...](https://trial.medpath.com/news/5c43f09ebb6d0f8e/ozempic-shows-anti-aging-effects-in-first-clinical-trial-reversing-biological-age-by-3-1-years)

trial.medpath.com Aug 1, 2025

[](https://trial.medpath.com/news/5c43f09ebb6d0f8e/ozempic-shows-anti-aging-effects-in-first-clinical-trial-reversing-biological-age-by-3-1-years)

### [Ozempic and Wegovy slow down biological ageing; creation of ...](https://www.newscientist.com/podcasts/ozempic-and-wegovy-slow-down-biological-ageing-creation-of-synthetic-bacterium-geology-of-the-russian-earthquake/)

newscientist.com Jun 3, 2025

[](https://www.newscientist.com/podcasts/ozempic-and-wegovy-slow-down-biological-ageing-creation-of-synthetic-bacterium-geology-of-the-russian-earthquake/)

### [New study reveals Ozempic could have shocking effect on ageing](https://www.uniladtech.com/science/news/ozempic-ageing-effect-shocking-new-study-reveals-110295-20250801)

uniladtech.com Aug 1, 2025

[](https://www.uniladtech.com/science/news/ozempic-ageing-effect-shocking-new-study-reveals-110295-20250801)

### [Ozempic really could turn back the clock on your biological age | New Scientist](https://www.newscientist.com/article/2490174-ozempic-really-could-turn-back-the-clock-on-your-biological-age/)

newscientist.com Aug 1, 2025

[](https://www.newscientist.com/article/2490174-ozempic-really-could-turn-back-the-clock-on-your-biological-age/)

### Trending News

[1 #### Vertex Pharmaceuticals Discontinues VX-993 Development After Phase 2 Failure in Acute Pain 2 days ago](https://trial.medpath.com/news/1e773ce416b8124e/vertex-pharmaceuticals-discontinues-vx-993-development-after-phase-2-failure-in-acute-pain)

[2 #### FDA Grants First Accelerated Approval for H3 K27M-Mutated Diffuse Midline Glioma with Dordaviprone 15 hours ago](https://trial.medpath.com/news/7f9a29a394a475ca/fda-grants-first-accelerated-approval-for-h3-k27m-mutated-diffuse-midline-glioma-with-dordaviprone)

[3 #### FDA Approves First CGRP Antagonist for Pediatric Migraine Prevention as Ajovy Expands to Children a day ago](https://trial.medpath.com/news/fcccf45fff3d53c0/fda-approves-first-cgrp-antagonist-for-pediatric-migraine-prevention-as-ajovy-expands-to-children)

[4 #### Polpharma Biologics and Fresenius Kabi Partner on Vedolizumab Biosimilar for Inflammatory Bowel Disease 2 days ago](https://trial.medpath.com/news/59030f0bee78f388/polpharma-biologics-and-fresenius-kabi-partner-on-vedolizumab-biosimilar-for-inflammatory-bowel-disease)

[5 #### FDA Provides Positive Feedback on Immutep's Eftilagimod Alfa for Head and Neck Cancer Treatment 2 days ago](https://trial.medpath.com/news/ebd838e4018001b2/fda-provides-positive-feedback-on-immutep-s-eftilagimod-alfa-for-head-and-neck-cancer-treatment)

[6 #### INmune Bio's INKmune Therapy Meets Primary Endpoints in Phase 1/2 Prostate Cancer Trial 3 days ago](https://trial.medpath.com/news/52741da96df523d5/inmune-bio-s-inkmune-therapy-meets-primary-endpoints-in-phase-1-2-prostate-cancer-trial)

[7 #### FDA Approves Tocilizumab-anoh Biosimilar for Cytokine Release Syndrome Treatment 19 hours ago](https://trial.medpath.com/news/e9a47512bf67aed6/fda-approves-tocilizumab-anoh-biosimilar-for-cytokine-release-syndrome-treatment)

[8 #### SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for $412 Million, Expanding Rare Oncology Portfolio 2 days ago](https://trial.medpath.com/news/531148ded87d0bda/serb-pharmaceuticals-to-acquire-y-mabs-therapeutics-for-412-million-expanding-rare-oncology-portfolio)

[9 #### Medicus Pharma and HelixNano Partner to Develop Needle-Free, Heat-Stable mRNA Vaccines 3 days ago](https://trial.medpath.com/news/605fdba67f73ed1b/medicus-pharma-and-helixnano-partner-to-develop-needle-free-heat-stable-mrna-vaccines)

[10 #### SOPHiA GENETICS and AstraZeneca Expand AI Partnership to Optimize Breast Cancer Treatment Outcomes 2 days ago](https://trial.medpath.com/news/221e6315228886c9/sophia-genetics-and-astrazeneca-expand-ai-partnership-to-optimize-breast-cancer-treatment-outcomes)

![Image 4: Subscribe Icon](https://trial.medpath.com/icon_subscribe_email.webp)
Daily Pharma Insights
---------------------

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

*   Critical clinical trial updates & results
*   Regulatory approvals & strategic partnerships
*   Market access decisions & commercial developments

Subscribe Now

### MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

#### Product

*   [Clinical Trial Search](https://trial.medpath.com/clinical-trial)
*   [AI Research Assistant](https://trial.medpath.com/research)
*   [Drug Database](https://trial.medpath.com/drug)
*   [Pricing Plans](https://trial.medpath.com/pricing)

#### Company

*   [News & Updates](https://trial.medpath.com/news)
*   [Organizations](https://trial.medpath.com/organization)
*   [FAQ](https://trial.medpath.com/faq)
*   [Search](https://trial.medpath.com/search)

#### Legal

*   [Privacy Policy](https://trial.medpath.com/privacy)
*   [Terms & Conditions](https://trial.medpath.com/terms)

© 2025 MedPath, Inc. All rights reserved.